Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by yvernigon Oct 13, 2020 9:32am
196 Views
Post# 31706366

REMINDER

REMINDERPR AFTERMARKET ON OCT 8TH:

• Salvia PCR tests are used to detect the SARS-CoV-2 RNA and will be processed in the Company’s lab in Virginia in the same way that the PCR nasopharyngeal tests are done.
• Antigen testing offers a way to immediately determine if a person showing symptoms is infected with SARS-CoV-2 and may therefore infect others. The tests are generally only indicated for the screening of symptomatic patients.
• The Respiratory Panel will be a highly accurate PCR-based test for 18 viruses and two respiratory bacteria. It will screen for Influenza A, Influenza B, and RSV, amongst the 18 viruses. Testing for multiple respiratory pathogens will not just rule out SARS-CoV-2 infection, but aid physicians in proper patient diagnosis.


<< Previous
Bullboard Posts
Next >>